Zacks: Brokerages Anticipate Heat Biologics Inc (HTBX) Will Announce Earnings of -$0.06 Per Share

Share on StockTwits

Wall Street brokerages expect Heat Biologics Inc (NASDAQ:HTBX) to post earnings of ($0.06) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Heat Biologics’ earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at $0.09. Heat Biologics reported earnings of ($0.60) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 90%. The firm is scheduled to report its next earnings results on Monday, November 12th.

According to Zacks, analysts expect that Heat Biologics will report full year earnings of ($0.69) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.62). For the next financial year, analysts anticipate that the business will report earnings of ($0.72) per share, with EPS estimates ranging from ($0.75) to ($0.70). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Heat Biologics.

Heat Biologics (NASDAQ:HTBX) last released its quarterly earnings data on Tuesday, August 14th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.09). Heat Biologics had a negative net margin of 437.62% and a negative return on equity of 116.28%. The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.11 million.

A number of equities analysts have recently weighed in on HTBX shares. Brookline Cap M reiterated a “buy” rating on shares of Heat Biologics in a research note on Wednesday, August 1st. HC Wainwright started coverage on Heat Biologics in a research note on Tuesday, June 26th. They set a “buy” rating and a $6.00 target price on the stock. Finally, Eurobank EFG started coverage on Heat Biologics in a research note on Monday, July 9th. They set a “buy” rating and a $11.00 target price on the stock.

An institutional investor recently bought a new position in Heat Biologics stock. Northern Trust Corp acquired a new position in shares of Heat Biologics Inc (NASDAQ:HTBX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 51,512 shares of the biopharmaceutical company’s stock, valued at approximately $111,000. Northern Trust Corp owned 0.22% of Heat Biologics at the end of the most recent reporting period. Institutional investors own 4.41% of the company’s stock.

HTBX opened at $1.82 on Monday. Heat Biologics has a 12-month low of $1.09 and a 12-month high of $7.21.

Heat Biologics Company Profile

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

See Also: Short Selling – Explanation For Shorting Stocks

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Q4 2018 EPS Estimates for Allergan plc Decreased by Analyst
Q4 2018 EPS Estimates for Allergan plc Decreased by Analyst
Shopify  Set to Announce Quarterly Earnings on Thursday
Shopify Set to Announce Quarterly Earnings on Thursday
Jefferies Financial Group  Scheduled to Post Earnings on Thursday
Jefferies Financial Group Scheduled to Post Earnings on Thursday
Critical Comparison: Qiwi  versus Tabula Rasa HealthCare
Critical Comparison: Qiwi versus Tabula Rasa HealthCare
Hotel Chocolat Group’s  Buy Rating Reiterated at Liberum Capital
Hotel Chocolat Group’s Buy Rating Reiterated at Liberum Capital
Q4 2018 EPS Estimates for Navient Corp  Increased by Analyst
Q4 2018 EPS Estimates for Navient Corp Increased by Analyst


Leave a Reply

© 2006-2018 Ticker Report. Google+.